Similar Papers

Paper Title
Journal
Date
Author
POS1017 GUSELKUMAB PROVIDES CONTINUED IMPROVEMENT IN KEY DOMAINS OF PSORIATIC ARTHRITIS THROUGH 2 YEARS
L Coates ... P J Mease
Annals of the Rheumatic Diseases | VOL. 81
L Coates, et. al.L Coates ... P J Mease
23 May 2022
P172 Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
Laura C Coates ... Rebecca Bolce
Rheumatology | VOL. 60
Laura C Coates, et. al.Laura C Coates ... Rebecca Bolce
25 Apr 2021
Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments.
Laura C Coates ... Philip S Helliwell
The Journal of Rheumatology | VOL. 43
Laura C Coates, et. al.Laura C Coates ... Philip S Helliwell
15 Dec 2015
To DAPSA or not to DAPSA? That is not the question
Monika M Schoels ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. 78
Monika M Schoels, et. al.Monika M Schoels ... Daniel Aletaha
12 Jun 2019
View more papers

More From: RMD Open

Paper Title
Journal
Date
Author
Influence of sacroiliac joint variation on clinical features of axial spondyloarthritis: a comparative analysis
Carolina Dominguez Aleixo ... Fabian Proft
RMD Open | VOL. 11
Carolina Dominguez Aleixo, et. al.Carolina Dominguez Aleixo ... Fabian Proft
08 Feb 2025
OMERACT GCA phantom project: validation of a 3D-printed ultrasound training phantom for diagnosis of giant cell arteritis
Tobias Schremmer ... Valentin Sebastian Schäfer
RMD Open | VOL. 11
Tobias Schremmer, et. al.Tobias Schremmer ... Valentin Sebastian Schäfer
06 Feb 2025
Porphyromonas gingivalis associates with the presence of anti-citrullinated protein antibodies, but not with the onset of arthritis: studies in an at-risk population
Charlotte De Vries ... Karin Lundberg
RMD Open | VOL. 11
Charlotte De Vries, et. al.Charlotte De Vries ... Karin Lundberg
31 Jan 2025
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
Atul Deodhar ... Xenofon Baraliakos
RMD Open | VOL. 11
Atul Deodhar, et. al.Atul Deodhar ... Xenofon Baraliakos
31 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.